Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Hazard returned 55 record(s)
|
|
Sunday, 07/29/2018
|
An Innovative Approach to Identify Biomarker Signatures for Cancer Genetic Data with Survival Endpoints
Ming Wang, Pennsylvania State University; Zheng Li, Penn State Unviersity
|
Competing Risks Matter in the Analysis of Public Health Data: When and How?
Dahhay Lee, National Cancer Center; Hyunsoon Cho, National Cancer Center
|
Semiparametric Regression Analysis of Length-Biased Interval-Censored Data
Fei Gao, University of Washington; Kwun Chuen Gary Chan, University of Washington
|
Estimation in the Nested Case-Control Design Under Model Misspecification
Michelle Nuno; Daniel L. Gillen, University of California, Irvine
|
Sample Size Calculations for Non-Inferiority Trials Using the Concept of Proportional Time
Milind A Phadnis, University of Kansas Medical Center
|
Estimation in the Nested Case-Control Design Under Model Misspecification
Michelle Nuno; Daniel L. Gillen, University of California, Irvine
2:35 PM
|
An Innovative Approach to Identify Biomarker Signatures for Cancer Genetic Data with Survival Endpoints
Ming Wang, Pennsylvania State University; Zheng Li, Penn State Unviersity
2:50 PM
|
Competing Risks Matter in the Analysis of Public Health Data: When and How?
Dahhay Lee, National Cancer Center; Hyunsoon Cho, National Cancer Center
3:05 PM
|
Semiparametric Regression Analysis of Length-Biased Interval-Censored Data
Fei Gao, University of Washington; Kwun Chuen Gary Chan, University of Washington
3:20 PM
|
Sample Size Calculations for Non-Inferiority Trials Using the Concept of Proportional Time
Milind A Phadnis, University of Kansas Medical Center
3:25 PM
|
Kaplan-Meier Based Methods to Address Non-Proportional Hazard Issues
Bo Huang, Pfizer Inc.
4:05 PM
|
Sample Size and Power Calculation for Immuno-Oncology Clinical Trials
Binbing Yu, MedImmune, Inc.; Dongyue FU, MedImmune, Inc.; Hefei (Harry) Yang, MedImmune, Inc.
4:20 PM
|
Design and Analysis of Survival Trials with Treatment Crossover
Xiaodong Luo, Sanofi
4:25 PM
|
Case Studies of Non-Proportional Hazards in Oncology and Hematology Trials
Jingjing Ye, FDA
4:45 PM
|
Design and Analysis of Cancer Immunotherapy Trials with Potential Violation of Proportional Hazards Assumption
Xiaofei Wang, Duke University School of Medicine; Guangyu Yang , University of Michigan
5:05 PM
|
|
Monday, 07/30/2018
|
SurvBoost: An R Package for High-Dimensional Variable Selection in the Stratified Proportional Hazards Model via Gradient Boosting
Emily Morris, University of Michigan; Jian Kang, University of Michigan; Zhi He, University of Michigan; Yanming Li, University of Michigan; Yi Li, University of Michigan
|
Risk Analysis of Human Health Among Artisanal Small-Scale Gold Mining Area in Indonesia
Koji Kanefuji, Institute of Statistical Mathematics; Koyomi Nakazawa, Fukuoka Institute of Technology; Osamu Nagafuchi, Fukuoka Institute of Technology
|
Predictors of Hospitalization During a Medicare Skilled Nursing Facility Stay
Fei Han, The Hilltop Institute; Ian Stockwell, The Hilltop Institute
|
A Hybrid Method for the Stratified Mark-Specific Proportional Hazards Models with Missing Data, with Applications to Dengue Vaccine Efficacy Trials
Yanqing Sun, University of North Carolina At Charlotte; Li Qi, Biostatistics and Programming, Sanofi; Peter Gilbert, Fred Hutchinson Cancer Research Center; Fei Heng, University of North Carolina at Charlotte
9:15 AM
|
Predictors of Hospitalization During a Medicare Skilled Nursing Facility Stay
Fei Han, The Hilltop Institute; Ian Stockwell, The Hilltop Institute
9:40 AM
|
Pseduolikelihood for Clustered Time-To-Event Outcomes from Complex Surveys
Jing Wang
9:50 AM
|
Closed-Form Solutions for Group Sequential Design in Survival Trials with Non-Proportional Hazards
Jianliang Zhang, Medimmune, LLC; Erik Pulkstenis, AbbVie
10:05 AM
|
Achieving Optimal Power of Logrank Test with Random Treatment Time-Lag Effect
Zhenzhen Xu , FDA; Yongsoek Park, Unversity of Pittsburgh; Boguang Zhen, FDA; Bin Zhu, NIH/NCI
11:00 AM
|
Variable Selection in Partially Linear Additive Hazards Model with Grouped Covariates and a Diverging Number of Parameters
Xuewen Lu, University of Calgary; Arfan Afzal, University of Calgary
11:15 AM
|
Moral Hazard Effects of Bank Resolution Policies: Inferences from a Bayesian Nonparametric Study
Padma Sharma, UC Irvine
11:20 AM
|
Practical Considerations on the Challenges to the Design and Analysis of Immuno-Oncology Trials
Yabing Mai, AbbVie, Inc; Yue Shentu, Merck and Co Inc
11:50 AM
|
A Regression Model of Cumulative Incidence for Competing Risks Data with Time-Dependent Exposures
Xingyuan Li, University of Pittsburgh; Joyce Chung-Chou H Chang, University of Pittsburgh
12:05 PM
|
Estimating Survey Attrition Phases Using Change-Point Models
Camille Hochheimer, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University; Alex H Krist, Virginia Commonwealth University
2:05 PM
|
Sample Size Determination Under Non-Proportional Hazards
Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
2:20 PM
|
Goodness-of-Fit Tests in Proportional Hazards Models with Random Effects
Ingrid Van Keilegom, KU Leuven; Wenceslao Gonzalez Manteiga, University of Santiago de Compostela; Maria Dolores Martinez Miranda, University of Granada
2:55 PM
|
Innovative Approaches to Deal with Delayed Treatment Effect, Cure Fraction and Treatment Switching in Time-To-Event Data in Cancer Immuno-Therapies
Carl Di Casoli, Halozyme Therapeutics; Alessandro Previtali, Celgene; Jonathan Jaeger, Celgene; Marie-Laure Casaebaig, Celgene
3:05 PM
|
|
Tuesday, 07/31/2018
|
Projecting Age-Specific Death Probabilities at Advanced Ages Using the Mortality Laws of Gompertz and Wittstein
Peter Pflaumer
|
Generating Survival Times Using Cox Proportional Hazards Models with Cyclic Time-Varying Covariates
Yunda Huang, Fred Hutchinson Cancer Research Center; Lily Zhang, Fred Hutchinson Cancer Research Center; Zong Zhang, Interlake High School; Peter Gilbert, Fred Hutchinson Cancer Research Center
|
On Survival Tree Under the Dependency Between Failure and Censoring
Asanao Shimokawa, Tokyo University of Science; Etsuo Miyaoka, Tokyo University of Science
|
Estimating Survey Attrition Phases Using Change-Point Models
Camille Hochheimer, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University; Alex H Krist, Virginia Commonwealth University
|
Supervised Dimension Reduction for Large-Scale Genomic Data with Censored Survival Outcomes Under Possible Non-Proportional Hazards
Lauren Spirko, Temple University; Karthik Devarajan, Fox Chase Cancer Center
|
Incorporating Historical Information into the Analysis of Clinical Trials- a Case Study
Guochen Song, Biogen; Yiqing Tian, Q2 Sulotions; John Zhong, Biogen; Stacy Lindborg, Biogen Idec
8:50 AM
|
Systematic Review of Test/Estimation Approach in Comparative Cancer Clinical Studies with Time-To-Event Outcomes
Miki Horiguchi, Kitasato University; Hajime Uno, Dana Farber Cancer Institute
9:05 AM
|
Semiparametric Single-Index Models for Optimal Treatment Regimes with Censored Outcomes
Jin Wang, University of North Carolina at Chapel Hill; Danyu Lin, University of North Carolina; Donglin Zeng, UNC Chapel Hill
10:35 AM
|
A Graphical Dissection of the Log-Rank Test and Cox Proportional Hazards Model
Xiaofei Hu, Abbvie; Yabing Mai, AbbVie, Inc
10:35 AM
|
Supervised Dimension Reduction for Large-Scale Genomic Data with Censored Survival Outcomes Under Possible Non-Proportional Hazards
Lauren Spirko, Temple University; Karthik Devarajan, Fox Chase Cancer Center
11:00 AM
|
Modeling Overall Survival Under Immuno-Oncology Therapies with Long-Term Survival Models
Junshui Ma, Merck & Co., Inc.; Keaven Anderson, Merck & Co., Inc.
11:35 AM
|
Choosing the Primary Efficacy Analysis for a Randomized Clinical Trial with Competing Risks
Eric Leifer, National Heart, Lung, and Blood Institute; James Troendle, National Institutes of Health; Lauren Kunz, National Heart, Lung, and Blood Institute
2:05 PM
|
|
Wednesday, 08/01/2018
|
WORKING LIFE EXPECTANCY of MAJOR LEAGUE PITCHERS and FORECASTING the NUMBER of THEM: TASKS MADE EASY by USING the COHORT CHANGE RATIO METHOD
David Swanson, University of California Riverside; Jeff Tayman, University of California San Diego; Lucky Tedrow, Western Washington University; Jack Baker, Health Fitness Corporation
|
Moving Beyond Longrank/Hazard Ratio Test/Estimation Approach in Cancer Clinical Trials
Hajime Uno, Dana Farber Cancer Institute; Miki Horiguchi, Kitasato University
8:35 AM
|
Incorporating Intermediary Information in Cox Models of Randomized Clinical Trials: The Information Balanced Intermediary Cox Model
James Troendle, National Institutes of Health; Eric Leifer, National Heart, Lung, and Blood Institute; Lauren Kunz, National Heart, Lung, and Blood Institute; Song Yang, NHLBI/NIH
8:50 AM
|
WORKING LIFE EXPECTANCY of MAJOR LEAGUE PITCHERS and FORECASTING the NUMBER of THEM: TASKS MADE EASY by USING the COHORT CHANGE RATIO METHOD
David Swanson, University of California Riverside; Jeff Tayman, University of California San Diego; Lucky Tedrow, Western Washington University; Jack Baker, Health Fitness Corporation
9:35 AM
|
Weighted Log-Rank Test for Time-To-Event Data in Immunotherapy Trials with Random Delayed Treatment Effect and Cure Rate
Shufang Liu, Astellas Pharma; Chenghao Chu, Indiana University, Fairbanks School of Public Health; Alan Rong, Data Science, Astellas Pharma Inc.
9:35 AM
|
A Functional Proportional Hazards Model for Investigating the Gene-Environment Interaction Effects on Survival
Li Luo, University of New Mexico
10:05 AM
|
A Simulation Study of Consistency Evaluation Between Local and Global Results in Multi-Regional Clinical Trials
Chunsheng He, Bristol-Myers Squibb; Jingyi Lin, Duke University; Stephane Munier, Bristol-Myers Squibb; Shein-Chung Chow, Duke University; Lisa Ying
10:50 AM
|
Improving Testing and Description of Treatment Effect in Clinical Trials with Time-To-Event Outcomes
Song Yang, NHLBI/NIH
11:50 AM
|
|
Thursday, 08/02/2018
|
Variational Inference for Proportional Hazards Model with Power Prior in Oncology Studies
Bo Jin, Boston Biomedical Inc.; Yue Chang, Boston Biomedical Inc
8:35 AM
|
Dynamic Prediction of Competing Risk Events using Landmark Sub-distribution Hazard Model with Multivariate Longitudinal Biomarkers
Cai Wu, Merck & Co.; Liang Li, UT MD Anderson Cancer Center; Ruosha Li, University of Texas School of Public Health
8:50 AM
|
Adjusting for Handling Effects in Microarray Data for Prognostic Biomarker Discovery and Survival Risk Prediction
Ai Ni, Memorial Sloan Kettering Cancer Center; Mengling Liu, New York University; Li-Xuan Qin, Memorial Sloan Kettering Cancer Center
9:05 AM
|
Yakovlev Promotion Time Cure Model with Local Polynomial Estimation
Li-Hsiang Lin, Georgia Tech; Li-Shan Huang, Institute of Statistics, National Tsing Hua University, TAIWAN
9:55 AM
|
|
|
